Novel N -Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential

Journal of Medicinal Chemistry

Volumn 58, Issue 12, 2015, Pages 4998-5014

  De La Fuente Revenga, Mario ^a   Fernández Sáez, Nerea ^a   Herrera Arozamena, Clara ^a   Morales García, José A ^b,c   Alonso Gil, Sandra ^b,c   Pérez Castillo, Ana ^b,c   Caignard, Daniel Henri ^d   Rivara, Silvia ^e   Rodríguez Franco, María Isabel ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUT DE RECHERCHES SERVIER   (France)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 OXADIAZOLE DERIVATIVE; 1,3,4 OXADIAZOLE DERIVATIVE; ACETAMIDE DERIVATIVE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; OXAZOLE DERIVATIVE; 1,3,4-OXADIAZOLE; 1,3,4-THIADIAZOLE; MELATONIN; MELATONIN RECEPTOR; OXADIAZOLE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; IN VITRO STUDY; MALE; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PHYSICOCHEMICAL MODEL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; CYTOLOGY; DRUG EFFECTS; HUMAN; METABOLISM; WISTAR RAT;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETULUS; HUMANS; MALE; MELATONIN; MODELS, MOLECULAR; NEURAL STEM CELLS; NEUROGENESIS; OXADIAZOLES; RATS; RATS, WISTAR; RECEPTORS, MELATONIN; THIADIAZOLES;

EID: 84933055330     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00245     Document Type: Article

References (88)

1. Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin-a pleiotropic, orchestrating regulator molecule Prog. Neurobiol. 2011, 93, 350-384
2. Zlotos, D. P.; Jockers, R.; Cecon, E.; Rivara, S.; Witt-Enderby, P. A. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential J. Med. Chem. 2014, 57, 3161-3185
3. Pala, D.; Lodola, A.; Bedini, A.; Spadoni, G.; Rivara, S. Homology models of melatonin receptors: challenges and recent advances Int. J. Mol. Sci. 2013, 14, 8093-8121
4. Mor, M.; Rivara, S.; Pala, D.; Bedini, A.; Spadoni, G.; Tarzia, G. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists Expert Opin. Ther. Pat. 2010, 20, 1059-1077
5. Pala, D.; Beuming, T.; Sherman, W.; Lodola, A.; Rivara, S.; Mor, M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement J. Chem. Inf. Model. 2013, 53, 821-835
6. Rivara, S.; Diamantini, G.; Di Giacomo, B.; Lamba, D.; Gatti, G.; Lucini, V.; Pannacci, M.; Mor, M.; Spadoni, G.; Tarzia, G. Reassessing the melatonin pharmacophore-Enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue Bioorg. Med. Chem. 2006, 14, 3383-3391
7. Jansen, J. M.; Copinga, S.; Gruppen, G.; Molinari, E. J.; Dubocovich, M. L.; Grol, C. J. The high affinity melatonin binding site probed with conformationally restricted ligands-I. Pharmacophore and minireceptor models Bioorg. Med. Chem. 1996, 4, 1321-1332
8. Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P. r.; Howell, H. E.; Renard, P.; Caignard, D.-H.; Pfeiffer, B.; Delagrange, P. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands J. Med. Chem. 1994, 37, 3231-3239
9. Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Imai, Y.; Hinuma, S.; Kato, K.; Nishikawa, H.; Hirai, K.; Miyamoto, M.; Ohkawa, S. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists J. Med. Chem. 2002, 45, 4222-4239
10. Tsotinis, A.; Afroudakis, P. A.; Garratt, P. J.; Bocianowska-Zbrog, A.; Sugden, D. Benzocyclobutane, benzocycloheptane and heptene derivatives as melatonin agonists and antagonists ChemMedChem 2014, 9, 2238-2243
11. Rivara, S.; Lorenzi, S.; Mor, M.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Tarzia, G. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models J. Med. Chem. 2005, 48, 4049-4060
12. Dubocovich, M. L. Luzindole (N-0774): a novel melatonin receptor antagonist J. Pharmacol. Exp. Ther. 1988, 246, 902-910
13. Laudon, M.; Zisapel, N. Characterization of central melatonin receptors using 125I-melatonin FEBS Lett. 1986, 197, 9-12
14. Vakkuri, O.; Lämsä, E.; Rahkamaa, E.; Ruotsalainen, H.; Leppäluoto, J. Iodinated melatonin: preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy Anal. Biochem. 1984, 142, 284-289
15. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
16. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
17. Arnott, J. A.; Planey, S. L. The influence of lipophilicity in drug discovery and design Expert Opin. Drug Discovery 2012, 7, 863-875
18. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
19. Leclerc, V.; Fourmaintraux, E.; Depreux, P.; Lesieur, D.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D. H.; Pfeiffer, B.; Delagrange, P.; Guardiola-Lemaître, B.; Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands Bioorg. Med. Chem. 1998, 6, 1875-1887
20. Willis, G. L. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease Drug News Perspect. 2005, 18, 437-444
21. Morgan, P. J.; Williams, L. M.; Davidson, G.; Lawson, W.; Howell, E. Melatonin receptors on ovine pars tuberalis: characterization and autoradiographicai localization J. Neuroendocrinol. 1989, 1, 1-4
22. Laudon, M.; Peleg-Shulgman, T. Pyrone-indole derivatives and process for their preparation. US 7,635,710 B2, 2009.
23. He, P.; Ouyang, X.; Zhou, S.; Yin, W.; Tang, C.; Laudon, M.; Tian, S. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease Horm. Behav. 2013, 64, 1-7
24. Tian, S.-W.; Laudon, M.; Han, L.; Gao, J.; Huang, F.-L.; Yang, Y.-F.; Deng, H.-F. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models Acta Pharmacol. Sin. 2010, 31, 775-783
25. Rami, M.; Landagaray, E.; Ettaoussi, M.; Boukhalfa, K.; Caignard, D.-H.; Delagrange, P.; Berthelot, P.; Yous, S. Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands Molecules 2012, 18, 154-166
26. Boström, J.; Hogner, A.; Llinàs, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in medicinal chemistry J. Med. Chem. 2011, 55, 1817-1830
27. Shen, H.-W.; Jiang, X.-L.; Winter, J. C.; Yu, A.-M. Psychedelic 5-methoxy- N, N -dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions Curr. Drug Metab. 2010, 11, 659-666
28. Duncan, M. J.; Takahashi, J. S.; Dubocovich, M. L. 2-[125I]Iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution Endocrinology 1988, 122, 1825-1833
29. Basarab, G. S.; Manchester, J. I.; Bist, S.; Boriack-Sjodin, P. A.; Dangel, B.; Illingworth, R.; Sherer, B. A.; Sriram, S.; Uria-Nickelsen, M.; Eakin, A. E. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J. Med. Chem. 2002, 56, 8712-8735
30. Ramírez-Rodríguez, G.; Klempin, F.; Babu, H.; Benítez-King, G.; Kempermann, G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice Neuropsychopharmacology 2009, 34, 2180-2191
31. Kempermann, G.; Jessberger, S.; Steiner, B.; Kronenberg, G. Milestones of neuronal development in the adult hippocampus Trends Neurosci. 2004, 27, 447-452
32. Mongiat, L. A.; Schinder, A. F. Neuroscience. A price to pay for adult neurogenesis Science 2014, 344, 594-595
33. Duman, R. S.; Malberg, J.; Nakagawa, S. Regulation of adult neurogenesis by psychotropic drugs and stress J. Pharmacol. Exp. Ther. 2001, 299, 401-407
34. Rolando, C.; Taylor, V. Neural stem cell of the hippocampus: development, physiology regulation, and dysfunction in disease Curr. Top. Dev. Biol. 2014, 107, 183-206
35. Abdipranoto, A.; Wu, S.; Stayte, S.; Vissel, B. The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development CNS Neurol. Disord.: Drug Targets 2008, 7, 187-210
36. Iguichi, H.; Kato, K. I.; Ibayashi, H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects J. Clin. Endocrinol. Metab. 1982, 55, 27-29
37. Ramírez-Rodríguez, G.; Vega-Rivera, N. M.; Benítez-King, G.; Castro-García, M.; Ortiz-López, L. Melatonin supplementation delays the decline of adult hippocampal neurogenesis during normal aging of mice Neurosci. Lett. 2012, 530, 53-58
38. López, L. C.; Escames, G.; López, A.; García, J. A.; Doerrier, C.; Acuña-Castroviejo, D. Melatonin, neurogenesis, and aging brain Open Neuroendocrinol. J. 2010, 3, 121-133
39. Poeggeler, B. Melatonin, aging, and age-related diseases Endocrine 2005, 27, 201-212
40. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 2006, 49, 459-462
41. Fernández-Bachiller, M. I.; Pérez, C.; Campillo, N. E.; Páez, J. A.; González-Muñoz, G. C.; Usán, P.; García-Palomero, E.; López, M. G.; Villarroya, M.; García, A. G.; Martínez, A.; Rodríguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties ChemMedChem 2009, 4, 828-841
42. Spuch, C.; Antequera, D.; Fernández-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease Neurotoxic. Res. 2010, 17, 421-431
43. López-Iglesias, B.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Romero, A.; López, M. G.; Villarroya, M.; Conde, S.; Rodríguez-Franco, M. I. New melatonin- N, N -dibenzyl(N -methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease J. Med. Chem. 2014, 57, 3773-3785
44. de la Fuente Revenga, M.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Caignard, D. H.; Yáñez, M.; Gamo, A. M.; Rodríguez-Franco, M. I. Neurogenic potential assessment and pharmacological characterization of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (pinoline) and melatonin-pinoline hybrids ACS Chem. Neurosci. 2015, 6, 800-810
45. Verniest, G.; England, D.; De Kimpe, N.; Padwa, A. Synthesis of substituted β-carbolines via gold(III)-catalyzed cycloisomerization of N -propargylamides Tetrahedron 2010, 66, 1496-1502
46. Verniest, G.; Padwa, A. Gold- and silver-mediated cycloisomerizations of N -propargylamides Org. Lett. 2008, 10, 4379-4382
47. Kumar, V.; Kaur, S.; Kumar, S. ZrCl4 catalyzed highly selective and efficient Michael addition of heterocyclic enamines with α,β-unsaturated olefins Tetrahedron Lett. 2006, 47, 7001-7005
48. Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashita, H.; Uno, Y.; Onishi, T.; Uchiyama, N.; Kawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R.; Textor, G. P.; Snell, G. P.; Takizawa, M.; Itoh, F.; Kori, M. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain permeability J. Med. Chem. 2009, 52, 6270-6286
49. Zoumpoulakis, P.; Camoutsis, C.; Pairas, G.; Soković, M.; Glamočlija, J.; Potamitis, C.; Pitsas, A. Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies Bioorg. Med. Chem. 2012, 20, 1569-1583
50. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.-P.; Malpaux, B.; Guillaumet, G.; Lesieur, D. l.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J. A. New selective ligands of human cloned melatonin MT1 and MT2 receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561
51. Bard, B.; Martel, S.; Carrupt, P. A. High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media Eur. J. Pharm. Sci. 2008, 33, 230-240
52. Tan, H.; Semin, D.; Wacker, M.; Cheetham, J. An automated screening assay for determination of aqueous equilibrium solubility enabling SPR study during drug lead optimization J. Lab. Autom. 2005, 10, 364-373
53. Zubets, I. V.; Vergizov, S. N.; Yakovlev, S. I.; V'Yunov, K. A. Basicity and mechanism of transmission of electronic effects of substituents in the series of 2-amino-5-aryl-1,3,4-thiadiazoles Chem. Heterocycl. Compd. 1987, 23, 225-228
54. Ferrón, S. R.; Andreu-Agulló, C.; Mira, H.; Sánchez, P.; Marqués-Torrejón, M. A.; Fariñas, I. A combined ex/in vivo assay to detect effects of exogenously added factors in neural stem cells Nat. Protoc. 2007, 2, 849-859
55. Morales-García, J. A.; Luna-Medina, R.; Alfaro-Cervello, C.; Cortes-Canteli, M.; Santos, A.; García-Verdugo, J. M.; Pérez-Castillo, A. Peroxisome proliferator-activated receptor gamma ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo Glia 2011, 59, 293-307
56. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
57. Fernández-Bachiller, M. I.; Pérez, C.; Monjas, L.; Rademann, J.; Rodríguez-Franco, M. I. New tacrine-4-oxo-4 H -chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties J. Med. Chem. 2012, 55, 1303-1317
58. Conway, S.; Canning, S. J.; Howell, H. E.; Mowat, E. S.; Barrett, P.; Drew, J. E.; Delagrange, P.; Lesieur, D.; Morgan, P. J. Characterisation of human melatonin MT1 and MT2 receptors by CRE-luciferase reporter assay Eur. J. Pharmacol. 2000, 390, 15-24
59. Bedini, A.; Lucarini, S.; Spadoni, G.; Tarzia, G.; Scaglione, F.; Dugnani, S.; Pannacci, M.; Lucini, V.; Carmi, C.; Pala, D.; Rivara, S.; Mor, M. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives J. Med. Chem. 2011, 54, 8362-8372
60. Mattson, R. J.; Catt, J. D.; Keavy, D.; Sloan, C. P.; Epperson, J.; Gao, Q.; Hodges, D. B.; Iben, L.; Mahle, C. D.; Ryan, E.; Yocca, F. D. Indanyl piperazines as melatonergic MT2 selective agents Bioorg. Med. Chem. Lett. 2003, 13, 1199-1202
61. Durieux, S.; Chanu, A.; Bochu, C.; Audinot, V.; Coumailleau, S.; Boutin, J. A.; Delagrange, P.; Caignard, D.-H.; Bennejean, C.; Renard, P.; Lesieur, D.; Berthelot, P.; Yous, S. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II Bioorg. Med. Chem. 2009, 17, 2963-2974
62. Shida, C. S.; Castrucci, A. M. L.; Lamy-Freund, M. T. High melatonin solubility in aqueous medium J. Pineal Res. 1994, 16, 198-201
63. Csuk, R.; von Scholz, Y. Synthesis of racemic carbocyclic cyclopropanoid nucleoside analogues Tetrahedron 1995, 51, 7193-7206
64. O'Neil, M. J. The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals, 14 th ed., version 14.9; Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.: Kenilworth, NJ, 2012.
65. Glennon, R. A.; Titeler, M.; McKenney, J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents Life Sci. 1984, 35, 2505-2511
66. Nonaka, R.; Nagai, F.; Ogata, A.; Satoh, K. In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes Biol. Pharm. Bull. 2007, 30, 2328-2333
67. Cagnacci, A.; Krauchi, K.; Wirz-Justice, A.; Volpe, A. Homeostatic versus circadian effects of melatonin on core body temperature in humans J. Biol. Rhythms 1997, 12, 509-517
68. Glennon, R. A.; Dukat, M.; Grella, B.; Hong, S.; Costantino, L.; Teitler, M.; Smith, C.; Egan, C.; Davis, K.; Mattson, M. V. Binding of beta-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors Drug Alcohol Depend. 2000, 60, 121-132
69. Lange, C.; Mix, E.; Frahm, J.; Glass, A.; Müller, J.; Schmitt, O.; Schmöle, A.-C.; Klemm, K.; Ortinau, S.; Hübner, R.; Frech, M. J.; Wree, A.; Rolfs, A. Small molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells Neurosci. Lett. 2011, 488, 36-40
70. Jiang, W.; Zhang, Y.; Xiao, L.; Van Cleemput, J.; Ji, S.-P.; Bai, G.; Zhang, X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects J. Clin. Invest. 2005, 115, 3104-3116
71. Banasr, M.; Hery, M.; Printemps, R.; Daszuta, A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone Neuropsychopharmacology 2004, 29, 450-460
72. Benninghoff, J.; van der Ven, A.; Schloesser, R. J.; Moessner, R.; Moller, H. J.; Rujescu, D. The complex role of the serotonin transporter in adult neurogenesis and neuroplasticity. A critical review World J. Biol. Psychiatry 2012, 13, 240-247
73. Yu, S.; Levi, L.; Siegel, R.; Noy, N. Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ) J. Biol. Chem. 2012, 287, 42195-42205
74. Hardeland, R. Melatonin: signaling mechanisms of a pleiotropic agent BioFactors 2009, 35, 183-192
75. Masana, M. I.; Dubocovich, M. L. Melatonin receptor signaling: finding the path through the dark Sci. STKE 2001, pe39
76. Musshoff, U.; Riewenherm, D.; Berger, E.; Fauteck, J.-D.; Speckmann, E.-J. Melatonin receptors in rat hippocampus: molecular and functional investigations Hippocampus 2002, 12, 165-173
77. Ferguson, F. M.; Fedorov, O.; Chaikuad, A.; Philpott, M.; Muniz, J. R. C.; Felletar, I.; von Delft, F.; Heightman, T.; Knapp, S.; Abell, C.; Ciulli, A. Targeting low-druggability bromodomains: Fragment based screening and inhibitor design against the BAZ2B bromodomain J. Med. Chem. 2013, 56, 10183-10187
78. The effect of compounds 16 and 19 on impedance (MT1) and cAMP levels (MT2) was measured and compared to that of melatonin in Chinese hamster ovary cells expressing human recombinant MT receptors by cellular dielectric spectroscopy for MT1 and in a homogeneous time resolved fluorescent assay for MT2 by CEREP. The corresponding protocols can be found on the company Web site: www.cerep.fr.
79. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 2007, 320, 1-13
80. Rodríguez-Franco, M. I.; de la Fuente Revenga, M.; Pérez, C.; Pérez-Castillo, A.; Morales-García, J. A.; Alonso-Gil, S. Neurogenic compounds comprising melatonin and the efficacy thereof in in vivo experiments for use in the treatment of diseases of the nervous system. WO 2014154925 A1, 2014.
81. Neuville, P.; Schann, S. Melatonin derivatives and their use for treating neurological dysfunctions. WO 2004085392 A1, 2004.
82. Boularot, A.; Giglione, C.; Petit, S.; Duroc, Y.; Alves de Sousa, R.; Larue, V.; Cresteil, T.; Dardel, F.; Artaud, I.; Meinnel, T. Discovery and refinement of a new structural class of potent peptide deformylase inhibitors J. Med. Chem. 2007, 50, 10-20
83. Rensen, M. Cyclisation of 1-methyl-5-methoxyindole-3-propionic acid Bull. Soc. Chim. Belg. 1959, 68, 258-269
84. Piotrowska, H.; Serafin, B.; Wejroch-Matacz, K. New amidine derivatives of indole Pol. J. Pharmacol. Pharm. 1975, 27, 297-303
85. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J. P.; Malpaux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J. A. New selective ligands of human cloned melatonin MT1 and MT2 receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561
86. Fukatsu, K.; Uchikawa, O.; Kawada, M.; Yamano, T.; Yamashita, M.; Kato, K.; Hirai, K.; Hinuma, S.; Miyamoto, M.; Ohkawa, S. Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists J. Med. Chem. 2002, 45, 4212-4221
87. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
88. Morales-García, J. A.; Luna-Medina, R.; Alonso-Gil, S.; Sanz-Sancristóbal, M.; Palomo, V.; Gil, C.; Santos, A.; Martínez, A.; Pérez-Castillo, A. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo ACS Chem. Neurosci. 2012, 3, 963-971